A Biomathematical Model of Human Erythropoiesis under Erythropoietin and Chemotherapy Administration

PLoS ONE

Volumn 8, Issue 6, 2013, Pages

  Schirm, Sibylle ^a   Engel, Christoph ^a   Loeffler, Markus ^a   Scholz, Markus ^a  

^a UNIVERSITY OF LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ERYTHROPOIETIN; ERYTHROPOIETIN ALFA; ERYTHROPOIETIN BETA; ERYTHROPOIETIN DELTA; ETOPOSIDE; HEMOGLOBIN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PACLITAXEL; PLATINUM COMPLEX; PREDNISOLONE; PREDNISONE; PROCARBAZINE; UNCLASSIFIED DRUG; VINCRISTINE;

ANEMIA; ARTICLE; BONE MARROW CELL; CELL KINETICS; CELL MATURATION; CELL PROLIFERATION; CHEMOTHERAPY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CYTOTOXICITY; DRUG DOSE ESCALATION; DRUG MEGADOSE; ERYTHROCYTE; ERYTHROCYTE TRANSFUSION; ERYTHROID CELL; ERYTHROPOIESIS; FEEDBACK SYSTEM; HEMATOCRIT; HUMAN; INJECTION SITE; MATHEMATICAL MODEL; MULTIPLE CYCLE TREATMENT; PHARMACODYNAMICS; RETICULOCYTE; RISK ASSESSMENT; SIMULATION; BLOOD; PHYSIOLOGY; THEORETICAL MODEL;

ERYTHROCYTE TRANSFUSION; ERYTHROPOIESIS; ERYTHROPOIETIN; HUMANS; MODELS, THEORETICAL;

EID: 84878807785     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0065630     Document Type: Article

References (65)

1. Wunderlich A, Kloess M, Reiser M, Rudolph C, Truemper L, et al. (2003) Practicability and acute haematological toxicity of 2- and 3-weekly chop and choep chemotherapy for aggressive non-hodgkin's lymphoma: results from the nhl-b trial of the german high-grade non-hodgkin's lymphoma study group (dshnhl). Annals of Oncology 14: 881-893.
2. Engel C, Scholz M, Loeffler M, (2004) A computational model of human granulopoiesis to simulate the hematotoxic effects of multicycle polychemotherapy. Blood 104: 2323-2331.
3. Scholz M, Engel C, Loeffler M, (2006) Model-based design of chemotherapeutic regimens that account for heterogeneity in leucopoenia. Br J Haematol 132: 723-735.
4. Scholz M, Engel C, Apt D, Sankar S, Goldstein E, et al. (2009) Pharmacokinetic and pharmacodynamic modelling of the novel human granulocyte colony-stimulating factor derivative maxy-g34 and pegfilgrastim in rats. Cell Prolif 42: 823-837.
5. Scholz M, Schirm S, Wetzler M, Engel C, Loeffler M, (2012) Pharmacokinetic and-dynamic modelling of g-csf derivatives in humans. Theoretical Biology and Medical Modelling 9: 32 doi:10.1186/1742-4682-9-32.
6. Pantel K, Loeffler M, Bungart B, Wichmann H, (1990) A mathematical model of erythropoiesis in mice and rats. part 4: Differences between bone marrow and spleen. Cell Tissue Kinet 23: 283-297.
7. Pantel K (1987) Erweiterung eines kybernetischen Modelles der Erythropoese und dessen Anwendung für normale und pathologische Mäuse. Dissertation, Universität zu Köln (in German).
8. Wichmann H (1983) Computer modeling of erythropoiesis. In: Current Concepts in Erythropoiesis, Chapter V., John Wiley and Sons.
9. Wichmann H, Loeffler M (1985) Mathematical modeling of cell proliferation: Stem cell regulation in hemopoiesis, Vol. 1, 2. CRC Press.
10. Meyer G (2004) Charakterisierung der zellkinetischen Wirkungen bei exogener Applikation von Erythropoetin auf die Erythropoese des Menschen mit Hilfe eines mathematischen Kompartimentmodells. Dissertation, Universiẗat Leipzig (in German).
11. Scholz M, Engel C, Loeffler M, (2005) Modelling human granulopoiesis under polychemotherapy with g-csf support. J Math Biol 50: 397-439.
12. Scholz M, Gross A, Loeffler M, (2010) A biomathematical model of human thrombopoiesis under chemotherapy. J Theor Biol 264: 287-300.
13. Krzyzanski W, Wyska E, (2008) Pharmacokinetics and pharmacodynamics of erythropoietin receptor in healthy volunteers. Naunyn-Schmiedeberg's Arch Pharmacol 377: 637-645.
14. Kota J, Machavaram K, McLennan D, Edwards G, Porter C, et al. (2007) Lymphatic absorption of subcutaneously administered proteins: Influence of different injection sites on the absorption of darbepoetin alfa using a sheep model. Drug Metab Dispos 35: 2211-2217.
15. Pfreundschuh M, Truemper L, Kloess M, Schmits R, Feller A, et al. (2004) 2-weekly or 3-weekly chop chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the nhl-b2 trial of the dshnhl. Blood 104: 634-641.
16. Pfreundschuh M, Truemper L, Kloess M, Schmits R, Feller A, et al. (2004) 2-weekly or 3-weekly chop chemotherapy with or without etoposide for the treatment of young patients with good prognosis (normal ldh) aggressive lymphomas: results of the nhl-b1 trial of the dshnhl. Blood 104: 626-633.
17. Pfreundschuh M, Zwick C, Zeynalova S, Dührsen U, Pflüger KH, et al. (2008) Dose-escalated choep for the treatment of young patients with aggressive non-hodgkin's lymphoma: 2. results of 26 the randomized high-choep trial of the german high-grade non-hodgkin's lymphoma study group (dshnhl). Ann Oncol 19: 545-552.
18. Pfreundschuh M, Schubert J, Ziepert M, Schmits R, et al. (2008) Six versus eight cycles of bi-weekly chop-14 with or without rituximab in elderly patients with aggressive cd20+ b-cell lymphomas: a randomised controlled trial (ricover-60). Lancet Oncol 9: 105-116.
19. Diehl V, Franklin J, Pfreundschuh M, Lathan B, Paulus U, et al. (2003) Standard and increaseddose beacopp chemotherapy compared with copp-abvd for advanced hodgkin's disease. N Engl J Med 348.
20. Sieber M, Bredenfeld H, Josting A, Reineke T, Rueffer U, et al. (2003) 14-day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage hodgkin's lymphoma: results of a pilot study of the german hodgkin's lymphoma study group. J Clin Oncol 21: 1734-1739.
21. Loeffler M, Pantel K, Wulff H, Wichmann H, (1989) A mathematical model of erythropoiesis in mice and rats. part 1: Structure of the model. Cell Tissue Kinet 22: 13-30.
22. Zhu J, Emerson S, (2002) Hematopoietic cytokines, transcription factors and lineage commitment. Oncogene 21 (21): 3295-3313.
23. Sawada K, Krantz S, Kans J, Dessypris E, Sawyer S, et al. (1987) Purification of human erythroid colony-forming units and demonstration of specific binding of erythropoietin. J Clin Invest 80: 357-366.
24. Sawada K, Krantz S, Dai CH, Koury S, Horn S, et al. (1990) Purification of human erythroid colony-forming units and demonstration of the evolution of erythropoietin receptors. J Cell Phys 142: 219-230.
25. Macdougall I, Jones J, Robinson M, Miles J, Coles G, et al. (1991) Subcutaneous Erythropoietin Therapy: Comparison of Three Different Sites of Injection. In: Gurland HJ,Moran J, SamtlebenW, Scigalla P, Wieczorek L (eds): Erythropoietin in Renal and Non-Renal Anemias. Contrib Nephrol, Basel, Karger. 152-156.
26. Jensen J, Madsen J, Jensen L, Pedersen E, (1994) Reduction absorption and elimination of erythropoietin in uremia compared with healthy volunteers. J Am Soc Nephrol 5: 177-185.
27. Rechenberg I (1994) Evolutionsstrategie 94. Stuttgart: Frommann-Holzboog.
28. Schwefel H, (1984) Evolution strategies: A family of nonlinear optimization techniques based on imitating some principles of organic evolution. Ann Oper Res 1: 65-167.
29. Ycasd. available: https://sourceforge.net/projects/ycasd/, accessed 2013 april 12.
30. Zelenetz A, Hamlin P, Kewalramani T, Yahalom J, Nimer S, et al. (2003) Ifosfamide, carboplatin, etoposide (ice)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-hodgkins lymphoma. Annals of Oncology 14: i5-i10.
31. Souillard A, Audran M, Bressolle F, Gareau R, Duvallet A, et al. (1996) Recombinant human erythropoietin and pharmacodynamic parameters in athletes. interest of blood sampling for doping control. Br J Clin Pharmacol 42: 355-360.
32. Lundby C, Thomsen J, Boushel R, Koskolou M, Warberg J, et al. (2007) Erythropoietin treatment elevates haemoglobin concentration by increasing red cell volume and depressing plasma volume. J Physiol 578: 309-314.
33. Cheung W, Goon B, Guilfoyle M, Wachholtz M, (1998) Pharmacokinetics and pharmacodynamics of recombinant human erythropoietin after single and multiple subcutaneous doses to healthy subjects. Clin Pharmacol Ther 8: 309-317.
34. Wichmann H, Loeffler M, Pantel K, Wulff H, (1989) A mathematical model of erythropoiesis in mice and rats. part 2. stimulated erythropoiesis. Cell Tissue Kinet 22: 31-49.
35. Wulff H, Wichmann H, Loeffler M, Pantel K, (1989) A mathematical model of erythropoiesis in mice and rats. part 3. supressed erythropoiesis. Cell Tissue Kinet 22: 31-49.
36. Bélair J, Mackey M, Mahaffy J, (1995) Age-structured and two-delay models for erythropoiesis. Math Biosci 128: 317-346.
37. Banks H, Cole C, Schlosser P, Tran H, (2004) Modelling and optimal regulation of erythropoiesis subject to benzene intoxication. Math Biosci Eng 1: 15-48.
38. Fuertinger DH, Kappel F, Thijssen S, Levin NW, Kotanko P (2012) A model of erythropoiesis in adults with sufficient iron availability. J Math Biol DOI ---10.1007/s00285-012-0530-0.
39. Crauste F, Pujo-Menjouet L, Genieys S, Molina C, Gandrillon O, (2008) Adding self-renewal in committed erythroid progenitors improves the biological relevance of a mathematical model of erythropoiesis. J Theor Biol 250: 322-338.
40. Savill N, Chadwick W, Reece S (2009) Quantitative analysis of mechanisms that govern red blood cell age structure and dynamics during anaemia. PLoS Comput Biol 5.
41. Mahaffy J, Belair J, Mackey M, (1998) Hematopoietic model with moving boundary condition and state dependent delay: applications in erythropoiesis. J Theor Biol 190: 135-146.
42. Veng-Pedersen P, Chapel S, Schmidt R, Al-Huniti N, Cook R, et al. (2002) An integrated pharmacodynamic analysis of erythropoietin, reticulocyte, and hemoglobin responses in acute anemia. Pharm Res 19: 1630-1635.
43. Chapel S, Veng-Pedersen P, Schmidt R, Widness J, (2000) A pharmacodynamic analysis of erythropoietin-stimulated reticulocyte response in phlebotomized sheep. J Pharm Exp Ther 296: 346-351.
44. Woo S, Krzyzanski W, Jusko W, (2008) Pharmacokinetic model of chemotherapy induced anemia in rats. Cancer Chemother Pharmacol 62(1): 123-133.
45. Ait-Oudhia S, Scherrmann JM, Krzyzanski W, (2010) Simultaneous pharmacokinetics/pharmacodynamics modeling of recombinant human erythropoietin upon multiple intravenous dosing in rats. JPET 334: 897-910.
46. Lohrmann H, SchremlW(1982) Cytotoxic Drugs and the Granulopoietic System. Berlin: Springer.
47. Guminski A, Harnett P, deFazio A, (2001) Carboplatin and paclitaxel interact antagonistically in a megakaryoblast cell line-a potential mechanism for paclitaxel-mediated sparing of carboplatininduced thrombocytopenia. Cancer Chemother Pharmacol 48(3): 229-334.
48. Elliott S, Egrie J, Browne J, Lorenzini T, Busse L, et al. (2004) Control of rhuepo biological activity: the role of carbohydrate. Exp Hematol 32(12): 1146-1155.
49. Macdougall I (2002) Optimizing the use of erythropoietic agents- pharmacokinetic and pharmacodynamic considerations. Nephrol Dial Transplant 17 [Suppl 5]: 66-70.
50. Egrie J, Browne J (2001) Development and characterization of novel erythropoiesis stimulating protein (nesp). Nephrol Dial Transplant 16 [Suppl 3]: 3-13.
51. Faris P, Ritter M, (1998) Epoetin alfa. a bloodless approach for the treatment of perioperative anemia. Clin Orthop Relat Res 357: 60-67.
52. Jelkmann W (2006) Recombinant erythropoietins- the role of glycosylation in receptor binding, action and degradation, businessbriefing: European kidney and urological disease.
53. Macdougall I, Padhi D, Jang G (2007) Pharmacology of darbepoetin alfa. Nephrol Dial Transplant 22 [Suppl 4]: iv2-iv9.
54. Markham A, Bryson H, (1995) Epoetin alfa. a review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in nonrenal applications. Drugs 49: 232-254.
55. Flaharty K, Caro J, Erslev A, Whalen J, (1990) Pharmakokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Clin Pharmacol Ther 47: 557-564.
56. Hayashi N, Kinoshita H, Yukawa E, Higuchi S, (1998) Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production (7). Br J Clin Pharmacol 46: 11-19.
57. Smith W, Dowell J, Pratt R, (2007) Pharmacokinetics and pharmacodynamics of epoetin delta in two studies in healthy volunteers and two studies in patients with chronic kidney disease. Clinical Therapeutics 29: 1368-1380.
58. Agoram B, Sutjandra L, Sullivan J, (2006) Population pharmacokinetics of darbepoetin alfa in healthy subjects. Br J Clin Pharmacol 63: 41-52.
59. Pirker R, Ramlau R, Schuette W, Zatloukal P, Ferreira I, et al. (2008) Safety and efficacy of darbepoetin alfa in previously untreated extensive-stage small-cell lung cancer treated with platinum plus etoposide. J Clin Oncology 26.
60. Goldberg M, (1995) Erythropoesis, erythropoetin, and iron metabolism in elective surgery: Preoperative strategies for avoiding allogeneic blood exposure. Am J Surg 170: 37S-43S.
61. Togawa A, Tanaka T, Nagashima S, Keta H, Kobayashi Y, et al. (2004) A comparison of the bioequivalence of two formulations of epoetin alfa after subcutaneous injection. Br J Clin Pharmacol 58: 269-276.
62. McMahon F, Vargas R, Ryan M, Jain A, Abels R, et al. (1990) Pharmacokinetics and effects of recombinant human erythropoietin after intravenous and subcutaneous injections in healthy voluteers. Blood 76: 1718-1722.
63. Sörgel F, Thyroff-Friesinger U, Vetter A, Vens-Cappell B, Kinzig M, (2009) Bioequivalence of hx575 (recombinant human epoetin alfa) and a comparator epoetin alfa after multiple subcutaneous administrations. Pharmacology 38: 122-130.
64. Krzyzanski W, Jusko W, Wacholtz M, Minton N, Cheung W, (2005) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after multiple subcutaneous doses in healthy subjects. Eur J Pharm Sci 26: 295-306.
65. GBG. German breast group, available: http://www.germanbreastgroup.de/studien/adjuvant/gain/unterlagen.html accessed 2011 october 11.